Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil E Kay

Showing results (81-90 of 325) with videos related to

Pageof 33
Sort By:
Hematology. American Society of Hematology. Education Program|November 26, 2002
Chronic lymphocytic leukemiaNeil E Kay, Terry J Hamblin, Diane F Jelinek, et al.
Frontiers in Oncology|December 19, 2023
Comparison of the blood immune repertoire with clinical features in chronic lymphocytic leukemia patients treated with chemoimmunotherapy or ibrutinibBaustin M Welch, Bryce A Manso, Kimberly A Gwin, et al.
British Journal of Cancer|June 17, 2024
Aberrant activation of AXL may drive progression of squamous cell carcinoma in CLL patients: a mechanistic study with clinical implicationsSutapa Sinha, Ray Guo, Miles D Del Busso, et al.
American Journal of Hematology|March 26, 2016
Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemiaChadi Nabhan, Kari G Chaffee, Susan L Slager, et al.
Clinical Proteomics|May 8, 2026
Proteomic and phosphoproteomic signatures of disease progression in unmutated IGHV chronic lymphocytic leukemiaRenee C Tschumper, Neil E Kay, Sameer A Parikh, et al.
Blood|July 8, 2010
Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switchWei Ding, Traci R Knox, Renee C Tschumper, et al.
Leukemia Research|July 26, 2005
A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cellsNeil E Kay, Nancy D Bone, Yean K Lee, et al.
Leukemia Research|January 9, 2008
MBL or CLL: which classification best categorizes the clinical course of patients with an absolute lymphocyte count >or= 5 x 10(9) L(-1) but a B-cell lymphocyte count <5 x 10(9) L(-1)?Tait D Shanafelt, Neil E Kay, Tim G Call, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2012
Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemiaBruce D Cheson, John C Byrd, Kanti R Rai, et al.
Blood Cancer Journal|May 18, 2021
SIRT3 overexpression and epigenetic silencing of catalase regulate ROS accumulation in CLL cells activating AXL signaling axisGuru P Maiti, Sutapa Sinha, Hasan Mahmud, et al.
Pageof 33

Showing results (81-90 of 325) with videos related to

Sort By:
Pageof 33
Hematology. American Society of Hematology. Education Program|November 26, 2002
Chronic lymphocytic leukemiaNeil E Kay, Terry J Hamblin, Diane F Jelinek, et al.
Frontiers in Oncology|December 19, 2023
Comparison of the blood immune repertoire with clinical features in chronic lymphocytic leukemia patients treated with chemoimmunotherapy or ibrutinibBaustin M Welch, Bryce A Manso, Kimberly A Gwin, et al.
British Journal of Cancer|June 17, 2024
Aberrant activation of AXL may drive progression of squamous cell carcinoma in CLL patients: a mechanistic study with clinical implicationsSutapa Sinha, Ray Guo, Miles D Del Busso, et al.
American Journal of Hematology|March 26, 2016
Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemiaChadi Nabhan, Kari G Chaffee, Susan L Slager, et al.
Clinical Proteomics|May 8, 2026
Proteomic and phosphoproteomic signatures of disease progression in unmutated IGHV chronic lymphocytic leukemiaRenee C Tschumper, Neil E Kay, Sameer A Parikh, et al.
Blood|July 8, 2010
Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switchWei Ding, Traci R Knox, Renee C Tschumper, et al.
Leukemia Research|July 26, 2005
A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cellsNeil E Kay, Nancy D Bone, Yean K Lee, et al.
Leukemia Research|January 9, 2008
MBL or CLL: which classification best categorizes the clinical course of patients with an absolute lymphocyte count >or= 5 x 10(9) L(-1) but a B-cell lymphocyte count <5 x 10(9) L(-1)?Tait D Shanafelt, Neil E Kay, Tim G Call, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2012
Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemiaBruce D Cheson, John C Byrd, Kanti R Rai, et al.
Blood Cancer Journal|May 18, 2021
SIRT3 overexpression and epigenetic silencing of catalase regulate ROS accumulation in CLL cells activating AXL signaling axisGuru P Maiti, Sutapa Sinha, Hasan Mahmud, et al.
Pageof 33